Human Ehrlichiosis
Ehrlichiosis caused by gram negative, obligately intracellular bacteria belonging to the genus Ehrlichia of the family Anaplasmataceae, Order Rickettsiales and the alpha sub-division Proteobacteria. Though they have a characteristic Gram negative cell wall structure, they lack the important enzymes to synthesize cell membrane components likewise lipopolysaccharide and peptidoglycan. As intracellular pathogens, Ehrlichia reside in cytoplasmic membrane-bound vacuoles inside host cells by forming microcolonies called morulae, which is derived from the Latin word “morus” for mulberry. Morulae range 1.0 to 6.0 µm in diameter which may contain uniform or mixed cell types.
- Vectors and reservoirs
- Clinical manifestations
- Treatment
Related Conference of Human Ehrlichiosis
11th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
5th International conference on Vaccines, Vaccination and Immunization
Human Ehrlichiosis Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2024 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2024 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2024 (UK)
- Antibiotics - Antibiotics 2024 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2024 (UK)
- Antimicrobial Peptides - Antibiotics 2024 (UK)
- Antimicrobial Therapy - Antibiotics 2024 (UK)
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Clinical Trials of Antibiotics - Antibiotics 2024 (UK)
- Current research in antibiotic resistance - Antibiotics 2024 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2024 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2024 (UK)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunology & Vaccines - Antibiotics 2024 (UK)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Infectious Diseases - Antibiotics 2024 (UK)
- Mechanism and Evolution of Antibiotic Resistance - Antibiotics 2024 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2024 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2024 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2024 (UK)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2024 (UK)
- Pharmacology & Toxicology - Antibiotics 2024 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2024 (UK)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- The Next Generation Approach of Antibiotics - Antibiotics 2024 (UK)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)